Therapeutic effect of MIP-1α-recruited dendritic cells on preestablished solid and metastatic tumors

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 17-26

  Cao, Qi ^a   Jin, Yanliang ^b   Jin, Min ^a   He, Shan ^a   Gu, Qiaoli ^c   He, Songbing ^c   Qiu, Yuhua ^d   Ge, Hailiang ^a   Yoneyama, Hiroyuki ^e   Zhang, Yanyun ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d SOOCHOW UNIVERSITY   (China)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Dendritic cells; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELANOMA ANTIGEN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINE CCL3; CHEMOTAXIS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; RECEPTORS, CCR7; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

MUS;

EID: 77953610370     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.009     Document Type: Article

References (46)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 2006, 311:17-58.
3. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999, 50:507-529.
4. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 2002, 109:1519-1526.
5. O. Mazda, W.T.V. Germeraad, Tumor immunity and immuno gene therapy of cancer, in: O. Mazda (Ed.), Frontiers in Immuno-Gene Therapy, Research Signpost, Trivandrum, 2004, pp. 1-30.
6. Hu J., Yuan X., Belladonna M.L., Ong J.M., Wachsmann-Hogiu S., Farkas D.L., Black K.L., Yu J.S. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 2006, 66:8887-8896.
7. Cho H.I., Kim E.K., Park S.Y., Lee S.K., Hong Y.K., Kim T.G. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett. 2007, 258:189-198.
8. Nestle F.O., Farkas A., Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 2005, 17:163-169.
9. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., Kang W.K., Hong Y.K., Kim T.G. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006, 24:2860-2868.
10. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., Soiffer R.J., Jung K., Kuroda M.J., Letvin N.L., Greenfield E.A., Mihm M., Kutok J.L., Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. 2003, 100:3398-3403.
11. Brossart P., Brossart M.D.P. Dendritic cells in vaccination therapies of malignant diseases. Transfus. Apheresis. Sci. 2002, 27:183-186.
12. + hematopoietic progenitor cells. Int. J. Cancer 2000, 86:385-392.
13. Zhang Y., Yoneyama H., Wang Y., Ishikawa S., Hashimoto S., Gao J.L., Murphy P., Matsushima K. Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice. J. Natl. Cancer Inst. 2004, 96:201-209.
14. Bueler H., Mulligan R.C. Induction of antigenspecific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol. Med. 1996, 2:545-555.
15. Reed D.S., Romero P., Rimoldi D., Cerottini J.C., Schaack J., Jongeneel C.V. Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. Int. J. Cancer. 1997, 72:1045-1055.
16. Zhang Y., Mukaida N., Wang J., Harada A., Akiyama M., Matsushima K. Induction of dendritic cell differentiation by granulocyte-macrophage colony-stimulating factor stem cell factor and tumor necrosis factor alpha in vitro from lineage phenotypes-negative c-kit murine hematopoietic progenitor cells. Blood 1997, 90:4842-4853.
17. + bone marrow hematopoietic progenitor cells. Blood 1998, 92:118-128.
18. Yoneyama H., Matsuno K., Zhang Y., Murai M., Itakura M., Ishikawa S., Hasegawa G., Naito M., Asakura H., Matsushima K. Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J. Exp. Med. 2001, 193:35-49.
19. Yoneyama H., Harada A., Imai T., Baba M., Yoshie O., Zhang Y., Higashi H., Murai M., Asakura H., Matsushima K. Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J. Clin. Invest. 1998, 102:1933-1941.
20. Okada N., Mori N., Koretomo R., Okada Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Nakagawa S., Mayumi T., Fujita T., Yamamoto A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12:129-139.
21. Lee A.Y., Chang S.Y., Kim J.I., Cha H.R., Jang M.H., Yamamoto M., Kweon M.N. Dendritic cells in colonic patches and iliac lymph nodes are essential in mucosal IgA induction following intrarectal administration via CCR7 interaction. Eur. J. Immunol. 2008, 38:1127-1137.
22. Klein C., Bueler H., Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 2000, 191:1699-1708.
23. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 1997, 186:1183-1187.
24. Itoh K., Hayashi A., Nakao M., Hoshino T., Seki N., Shichijo S. Human tumor rejection antigens MAGE. J. Biochem. 1996, 119:385-390.
25. Lucas S., De Smet C., Arden K.C., Viars C.S., Lethe B., Lurquin C., Boon T. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 1998, 58:743-752.
26. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7:790-802.
27. Russo V., Cipponi A., Raccosta L., Rainelli C., Fontana R., Maggioni D., Lunghi F., Mukenge S., Ciceri F., Bregni M., Bordignon C., Traversari C. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J. Clin. Invest. 2007, 117:3087-3096.
28. Germain R.N., Margulies D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993, 11:403-450.
29. Schnurr M., Galambos P., Scholz C., Then F., Dauer M., Endres S., Eigler A. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001, 61:6445-6450.
30. S Diebold S., Cotten M., Koch N., Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 2001, 8:487-493.
31. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A., Roberts B.L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 1999, 163:699-707.
32. Schumacher L., Ribas A., Dissette V.B., McBride W.H., Mukherji B., Economou J.S., Butterfield L.H. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother. 2004, 27:191-200.
33. Vulink A., Radford K.J., Melief C., Hart D.N. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 2008, 99:363-407.
34. Lopes L., Fletcher K., Ikeda Y., Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother. 2006, 55:1011-1016.
35. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5:296-306.
36. Reschner A., Hubert P., Delvenne P., Boniver J., Jacobs N. Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin. Exp. Immunol. 2008, 152:219-226.
37. Fernandez N.C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 1999, 5:405-411.
38. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
39. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
40. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003, 63:3281-3288.
41. Adema G.J., de Vries I.J., Punt C.J., Figdor C.G. Migration of dendritic cell based cancer vaccines: in vivo veritas?. Curr. Opin. Immunol. 2005, 17:170-174.
42. Chen Z., Moyana T., Saxena A., Warrington R., Jia Z., Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer. 2001, 93:539-548.
43. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., Figdor C.G., Adema G.J. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999, 59:3340-3345.
44. Smith A.L., Fazekas de St Groth B. Antigen-pulsed CD8α dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med. 1999, 189:593-598.
45. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999, 59:56-58.
46. Yoneyama H., Narumi S., Zhang Y., Murai M., Baggiolini M., Lanzavecchia A., Ichida T., Asakura H., Matsushima K. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 2002, 195:1257-1266.